Dr. Reddy's Laboratories

Price chart

Previous close

₹1,370.00

Open

₹1,375.00

Day high

₹1,390.30

Day low

₹1,369.30

Listed on NSE since 30 May 2003.

Futures and options

Futures, 23 Nov expiry

₹1,390.10

Premium to the share price

+5.10 (+0.37%)

Futures open interest

25,835 contracts (+413 today)

Lot size (NOV 26)

625 shares

Source: NSE, 09-Nov-2026 11:58:28, delayed. Option chain · All futures · Lot sizes

Pivot levels

R3

1,392.47

R2

1,382.73

R1

1,377.87

CPR top

1,370.57

Pivot

1,368.13

CPR bottom

1,365.70

S1

1,363.27

S2

1,353.53

S3

1,348.67

From Friday 6 November’s high, low and close (Yahoo Finance). Arithmetic on past prices, not a forecast.

Market value

₹1,15,296 Cr

P/E (trailing)

41.17

EPS (trailing)

₹33.59

Price to book

2.98

Dividend yield

0.58%

Return on equity

7.3%

Debt to equity

0.19

Profit margin

8.5%

Beta

0.20

Volume today

7.28 L

Average volume

19.52 L

Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.

Source: Yahoo Finance, from annual reports. Consolidated where reported.

Source: Dr. Reddy's Laboratories’s results filed with NSE, consolidated (the whole group). Net profit is the share of Dr. Reddy's Laboratories’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.

Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.

Source: Dr. Reddy's Laboratories’s half-yearly statements of assets and liabilities filed with NSE, consolidated. Companies file these every September and March.

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. Its Others segment engages in developing therapies in the fields of oncology and inflammation; and research, development, and commercialization of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines, vitamins and minerals, and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Industry

Drug Manufacturers - Specialty & Generic

Based in

Hyderabad

Employees

27,527

Company website · Profile: Yahoo Finance

No headlines name Dr. Reddy's Laboratories in the last day or two.

• Dividend - Rs 8 Per Share

  Dividend · ex-date 10 July 2026

• Dividend - Rs 8 Per Share

  Dividend · ex-date 10 July 2025

• Face Value Split (Sub-Division) - From Rs 5/- Per Share To Re 1/- Per Share

  Split · ex-date 28 October 2024

• Annual General Meeting/Dividend - Rs 40 Per Share

  Dividend · ex-date 16 July 2024

• Annual General Meeting/Dividend - Rs 40 Per Share

  Dividend · ex-date 11 July 2023

• Annual General Meeting/Dividend - Rs 30 Per Share

  Dividend · ex-date 11 July 2022

• Annual General Meeting/Dividend - Rs 25 Per Share

  Dividend · ex-date 9 July 2021

• Annual General Meeting/Dividend - Rs 25 Per Share

  Dividend · ex-date 13 July 2020

Source: NSE. Latest first, 8 of 20.